Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar

Detalles Bibliográficos
Autores principales: Fareed, Areeba, Inam, Nimrah, Faraz, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272631/
https://www.ncbi.nlm.nih.gov/pubmed/37333047
http://dx.doi.org/10.1177/20363613231183785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272631/
https://www.ncbi.nlm.nih.gov/pubmed/37333047
http://dx.doi.org/10.1177/20363613231183785

Ejemplares similares